680 related articles for article (PubMed ID: 27533882)
1. Update on elotuzumab, a novel anti-SLAMF7 monoclonal antibody for the treatment of multiple myeloma.
Lonial S; Kaufman J; Reece D; Mateos MV; Laubach J; Richardson P
Expert Opin Biol Ther; 2016 Oct; 16(10):1291-301. PubMed ID: 27533882
[TBL] [Abstract][Full Text] [Related]
2. Mechanisms of NK Cell Activation and Clinical Activity of the Therapeutic SLAMF7 Antibody, Elotuzumab in Multiple Myeloma.
Campbell KS; Cohen AD; Pazina T
Front Immunol; 2018; 9():2551. PubMed ID: 30455698
[TBL] [Abstract][Full Text] [Related]
3. Elotuzumab in the treatment of relapsed and refractory multiple myeloma.
Grosicki S; Bednarczyk M; Barchnicka A; Grosicka O
Future Oncol; 2021 May; 17(13):1581-1591. PubMed ID: 33478270
[TBL] [Abstract][Full Text] [Related]
4. Preclinical and clinical evaluation of elotuzumab, a SLAMF7-targeted humanized monoclonal antibody in development for multiple myeloma.
Palumbo A; Sonneveld P
Expert Rev Hematol; 2015 Aug; 8(4):481-91. PubMed ID: 26070331
[TBL] [Abstract][Full Text] [Related]
5. The role of SLAMF7 in multiple myeloma: impact on therapy.
Boudreault JS; Touzeau C; Moreau P
Expert Rev Clin Immunol; 2017 Jan; 13(1):67-75. PubMed ID: 27376202
[TBL] [Abstract][Full Text] [Related]
6. Elotuzumab in combination with lenalidomide and dexamethasone in patients with relapsed multiple myeloma: final phase 2 results from the randomised, open-label, phase 1b-2 dose-escalation study.
Richardson PG; Jagannath S; Moreau P; Jakubowiak AJ; Raab MS; Facon T; Vij R; White D; Reece DE; Benboubker L; Zonder J; Tsao LC; Anderson KC; Bleickardt E; Singhal AK; Lonial S;
Lancet Haematol; 2015 Dec; 2(12):e516-27. PubMed ID: 26686406
[TBL] [Abstract][Full Text] [Related]
7. Clinical potential of SLAMF7 antibodies - focus on elotuzumab in multiple myeloma.
Friend R; Bhutani M; Voorhees PM; Usmani SZ
Drug Des Devel Ther; 2017; 11():893-900. PubMed ID: 28356715
[TBL] [Abstract][Full Text] [Related]
8. The role of elotuzumab in the treatment of relapsed or refractory multiple myeloma.
Comeau JM; Kelly K; Jean GW
Am J Health Syst Pharm; 2018 Jan; 75(2):55-66. PubMed ID: 29317395
[TBL] [Abstract][Full Text] [Related]
9. Elotuzumab: a novel anti-CS1 monoclonal antibody for the treatment of multiple myeloma.
Lonial S; Kaufman J; Laubach J; Richardson P
Expert Opin Biol Ther; 2013 Dec; 13(12):1731-40. PubMed ID: 24151843
[TBL] [Abstract][Full Text] [Related]
10. Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma.
Lonial S; Dimopoulos M; Palumbo A; White D; Grosicki S; Spicka I; Walter-Croneck A; Moreau P; Mateos MV; Magen H; Belch A; Reece D; Beksac M; Spencer A; Oakervee H; Orlowski RZ; Taniwaki M; Röllig C; Einsele H; Wu KL; Singhal A; San-Miguel J; Matsumoto M; Katz J; Bleickardt E; Poulart V; Anderson KC; Richardson P;
N Engl J Med; 2015 Aug; 373(7):621-31. PubMed ID: 26035255
[TBL] [Abstract][Full Text] [Related]
11. Elotuzumab with lenalidomide and dexamethasone for Japanese patients with relapsed/refractory multiple myeloma: phase 1 study.
Iida S; Nagai H; Kinoshita G; Miyoshi M; Robbins M; Pandya D; Bleickardt E; Chou T
Int J Hematol; 2017 Mar; 105(3):326-334. PubMed ID: 27848182
[TBL] [Abstract][Full Text] [Related]
12. Immunotherapy: A New Approach to Treating Multiple Myeloma with Daratumumab and Elotuzumab.
Afifi S; Michael A; Lesokhin A
Ann Pharmacother; 2016 Jul; 50(7):555-68. PubMed ID: 27083916
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of elotuzumab for the treatment of multiple myeloma.
Gavriatopoulou M; Terpos E; Kastritis E; Dimopoulos MA
Expert Opin Drug Saf; 2017 Feb; 16(2):237-245. PubMed ID: 28060563
[TBL] [Abstract][Full Text] [Related]
14. Elotuzumab as a novel anti-myeloma immunotherapy.
Radhakrishnan SV; Bhardwaj N; Steinbach M; Weidner J; Luetkens T; Atanackovic D
Hum Vaccin Immunother; 2017 Aug; 13(8):1751-1757. PubMed ID: 28604269
[TBL] [Abstract][Full Text] [Related]
15. Anti-CD38 and anti-SLAMF7: the future of myeloma immunotherapy.
Zamagni E; Tacchetti P; Pantani L; Cavo M
Expert Rev Hematol; 2018 May; 11(5):423-435. PubMed ID: 29582696
[TBL] [Abstract][Full Text] [Related]
16. Elotuzumab: First Global Approval.
Markham A
Drugs; 2016 Mar; 76(3):397-403. PubMed ID: 26809244
[TBL] [Abstract][Full Text] [Related]
17. Elotuzumab: a novel immune-stimulating therapy to treat multiple myeloma.
Grosicki S; Barchnicka A
Expert Rev Hematol; 2016 Jul; 9(7):621-8. PubMed ID: 27322214
[TBL] [Abstract][Full Text] [Related]
18. Elotuzumab in combination with thalidomide and low-dose dexamethasone: a phase 2 single-arm safety study in patients with relapsed/refractory multiple myeloma.
Mateos MV; Granell M; Oriol A; Martinez-Lopez J; Blade J; Hernandez MT; Martín J; Gironella M; Lynch M; Bleickardt E; Paliwal P; Singhal A; San-Miguel J
Br J Haematol; 2016 Nov; 175(3):448-456. PubMed ID: 27434748
[TBL] [Abstract][Full Text] [Related]
19. Elotuzumab: A Review in Relapsed and/or Refractory Multiple Myeloma.
Lamb YN
Drugs; 2018 Sep; 78(14):1481-1488. PubMed ID: 30232695
[TBL] [Abstract][Full Text] [Related]
20. Enhanced SLAMF7 Homotypic Interactions by Elotuzumab Improves NK Cell Killing of Multiple Myeloma.
Pazina T; James AM; Colby KB; Yang Y; Gale A; Jhatakia A; Kearney AY; Graziano RF; Bezman NA; Robbins MD; Cohen AD; Campbell KS
Cancer Immunol Res; 2019 Oct; 7(10):1633-1646. PubMed ID: 31431433
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]